Alterity Therapeutics Ltd
corporate_fare Company Profile
Alterity Therapeutics Ltd (NASDAQ:ATHE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ATHE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ATHE spans 6-K, 20-F.
Recent high-impact activity:
- Alterity Therapeutics Prices 8.4M Share Placement at A$0.50, Raising A$4.2M
- Alterity Locks In A$4.2M Underwriting for ATHO Options to Fund Phase 3 MSA Trial
- Alterity 20-F: Going Concern, A$37.3M Cash, and FDA-Aligned Phase 3 Path for ATH434
- Alterity Therapeutics Secures U.S. Composition of Matter Patent for ATH434, Locking in Protection Through 2045
- Alterity Therapeutics Reports A$37.3M Cash, FDA-Aligned Phase 3 Path for ATH434 in MSA
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ATHE, detected from its recent SEC filings · based on capital-structure filings through 2026-07-29.
Option Expiry Notice · Potential Share Issuance
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
ATHE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.